Novo Nordisk launches Wegovy in India, a once-weekly weight-loss injection shown to aid obesity treatment and reduce heart ...

A new study analyzing NFHS-5 data reveals India’s most obese state. With alarming obesity rates across cities, experts warn ...

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

Novo Nordisk is making a strategic move into one of the world's fastest-growing obesity markets by launching its blockbuster ...

A recent study reveals that nearly 20% of Indian households have all adults classified as overweight, while 10% are obese.

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

Heart disease is increasingly impacting young Indian adults, with risks rising silently from age 40. Early screening and ...

CHENNAI: Danish drugs and insulin maker Novo Nordisk launched Wegovy, its latest and the much-awaited weight-loss drug -- a once‑a‑week semaglutide injection, i ...

Novo Nordisk decodes India’s obesity drug market with Wegovy positioned as once-a-week novel weight management medication: ...

Wegovy is the first drug in India approved for both weight management and risk reduction of major adverse cardiovascular events in individuals with established heart disease.

Obesity in India is a chronic disease, not a personal failure, requiring empathy, science-based treatment, and public health ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...